75. Cushing disease Clinical trials / Disease details
Clinical trials : 203 / Drugs : 191 - (DrugBank : 51) / Drug target genes : 62 - Drug target pathways : 128
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2016-002240-17-GB (EUCTR) | 16/05/2017 | 06/03/2017 | A Study of ATR-101 for the Treatment of Cushing’s Syndrome | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing’s Syndrome | endogenous Cushing’s syndrome MedDRA version: 20.0;Level: SOC;Classification code 10014698;Term: Endocrine disorders;System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: ATR-101 INN or Proposed INN: Nevanimibe hydrochloride Other descriptive name: ATR-101; CI-984 | Millendo Therapeutics, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 16 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United States;United Kingdom |